Sandbox Reserved 821: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
 
Line 83: Line 83:
[[Image:C1q.3.jpg]]
[[Image:C1q.3.jpg]]


<ref name="three">PMID:16493053</ref> C1 is the first component of the classical pathway of the complement and consists of a complex of one C1q, two C1r, and two C1s molecules. C1q is the recognition subunit whereas C1r and C1s form the catalytic subunit. C1q is composed of three different polypeptide chains A, B and C and has a total molecular mass of 460Da. Each chain is present in four copies in the C1q molecule. C1q can bind different activators such as immunoglobulin (IgM and IgG) and CRP. In red, adjacent bound CRP molecules may present multiple binding sites via the face A for the C1q arms.<ref name="first">PMID:10368284</ref>
C1 is the first component of the classical pathway of the complement and consists of a complex of one C1q, two C1r, and two C1s molecules. C1q is the recognition subunit whereas C1r and C1s form the catalytic subunit. C1q is composed of three different polypeptide chains A, B and C and has a total molecular mass of 460Da. Each chain is present in four copies in the C1q molecule. C1q can bind different activators such as immunoglobulin (IgM and IgG) and CRP. In red, adjacent bound CRP molecules may present multiple binding sites via the face A for the C1q arms.<ref>PMID:10368284</ref>


The bond of C1 to an activator, as CRP, triggers the activation of the classical pathway of the complement. This pathway permits, inter alia, the lysis of infectious agent. An excessive activation of the classical pathway could induce tissue injury in ischemia. Thus, the use of inhibitors that attenuate the activation of the pathway by CRP could be a therapeutic approach in ischemia injury.<ref name="three">PMID:16493053</ref>
The bond of C1 to an activator, as CRP, triggers the activation of the classical pathway of the complement. This pathway permits, inter alia, the lysis of infectious agent. An excessive activation of the classical pathway could induce tissue injury in ischemia. Thus, the use of inhibitors that attenuate the activation of the pathway by CRP could be a therapeutic approach in ischemia injury.<ref name="three">PMID:16493053</ref>